미국의 자궁근종 치료 기기 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 기술별, 치료 모드별, 부문 예측(2025-2030년)

U.S. Uterine Fibroids Treatment Devices Market Size, Share & Trends Analysis Report By Technology (Surgical Techniques, Laparoscopic Techniques), By Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment), And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,272,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,662,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,443,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

미국의 자궁근종 치료 기기 시장의 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 미국의 자궁근종 치료 기기 시장 규모는 2030년까지 47억 1,000만 달러에 달할 것으로 예측되며, 2025-2030년 연평균 복합 성장률(CAGR) 9.3%로 확대될 것으로 예측됩니다.

미국의 자궁근종 치료 기기 산업은 자궁근종 치료의 선택지에 대한 의식의 고조, 저침습 수술의 진보, 자궁 적출 수술에 대한 자궁 온존 수술에 대한 수요 증가에 의해 큰 성장을 이루고 있습니다. 더불어 생식 연령 여성의 자궁근종 유병률 증가, 혁신적인 치료 장치의 이용 가능성은 시장 확대를 촉진하는 주요 요인입니다.

자궁근종 치료 기기의 혁신은 환자의 치료를 계속 변화시키고 있습니다. 최근 FDA 승인과 제품 출시로 더 효과적이고 침습적인 치료 옵션에 대한 길이 열렸습니다. 2024년 9월, 증후성 자궁근종 저침습 솔루션에 특화된 의료기기 기업인 Gynesonics Inc.는 Sonata System용 새로운 SMART OS 2.4 소프트웨어 기술 출시를 발표했습니다. 이 혁신적인 치료는 최초이자 유일한 자궁내 초음파 시스템과 독자적인 선진적인 라디오파소작장치를 결합한 것으로, 증후성 자궁근종 치료에 절개를 필요로 하지 않고 자궁을 온존하며 경경관적인 선택지를 제공합니다. 이러한 진보는 손기술의 위험을 줄이면서 환자의 전귀를 개선한다는 업계의 약속을 강조하는 것입니다.

시장은 비 수술적이고 자궁 온존의 치료 접근법으로 이동하고 있습니다. 자궁적출술과 같은 전통적인 외과적 처치는 회복시간의 단축, 합병증의 감소, 환자의 삶의 질 향상을 제공하는 저침습성 방법으로 대체되고 있습니다. 자궁경하자궁근종핵출술, 복강경하자궁근종핵출술, 비침습적 초음파요법은 환자나 헬스케어 공급자들 사이에서 인기를 끌고 있습니다.

지속적인 기술 진보, 저침습 수술에 대한 보험 적용 확대, 여성의 재활용 건강에 대한 관심이 증가함에 따라 미국의 자궁근종 치료 기기 산업은 지속적인 성장을 이루려고 합니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 미국의 자궁근종 치료 기기 시장의 변수, 동향 및 범위

• 시장 계통 전망
  • 부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 미국의 자궁근종 치료 기기 시장 분석 툴
  • 업계 분석-Porter's Five Forces 분석
  • PESTEL 분석

제4장 미국의 자궁근종 치료 기기 시장 : 기술별 추정 및 동향 분석

• 부문 대시보드
• 미국의 자궁근종 치료 기기 시장 : 기술별 변동 분석
• 미국의 자궁근종 치료 기기 시장 : 기술별 규모 및 동향 분석(2018-2030년)
• 수술 기술
  • 자궁 적출술
  • 자궁근종 절제술
• 복강경 수술
  • 복강경하자궁근종절제술
  • 근육 융해
• 어블레이션 기술
  • 마이크로파 어블레이션
  • 뜨거운 물 절제
  • 동결요법
  • 초음파 절제
• 색전술

제5장 미국의 자궁근종 치료 기기 시장 : 치료 모드별 추정 및 동향 분석

• 부문 대시보드
• 미국의 자궁근종 치료 기기 시장 : 치료 모드별 변동 분석
• 미국의 자궁근종 치료 기기 시장 : 치료 모드별 규모 및 동향 분석(2018-2030년)
• 침습적 치료
• 저침습적 치료
• 비침습적 치료

제6장 경쟁 구도

• 시장 진출 기업의 분류
• 주요 기업 프로파일
• Medtronic
• Stryker
• Boston Scientific Corporation
• Insightec.
• CooperSurgical Inc.
• Hologic, Inc.
• CONMED Corporation.
• Merit Medical Systems.
• Minerva Surgical, Inc.

AJY

영문 목차

영문목차

U.S. Uterine Fibroids Treatment Devices Market Growth & Trends:

The U.S. uterine fibroids treatment devices market size is anticipated to reach USD 4.71 billion by 2030 and is anticipated to expand at a CAGR of 9.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The U.S. uterine fibroids treatment devices industry is experiencing significant growth due to the rising awareness of fibroid treatment options, advancements in minimally invasive procedures, and increasing demand for uterus-preserving alternatives to hysterectomy. In addition, the growing prevalence of uterine fibroids among women of reproductive age and the availability of innovative treatment devices are key factors driving market expansion.

Innovations in fibroid treatment devices continue to transform patient care. Recent FDA approvals and product launches have concreted the way for more effective and less invasive treatment options. In September 2024, Gynesonics Inc., a medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced the release of its new SMART OS 2.4 software technology for the Sonata System. This innovative treatment combines the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, offering an incision-free, uterus-preserving, transcervical option for treating symptomatic uterine fibroids. Such advancements highlight the industry's commitment to improving patient outcomes while reducing procedural risks.

The market is shifting toward non-surgical and uterus-sparing treatment approaches. Traditional surgical procedures, such as hysterectomy, are being replaced by less invasive methods that offer reduced recovery time, fewer complications, and improved quality of life for patients. Hysteroscopic myomectomy, laparoscopic myomectomy, and non-invasive ultrasound therapy are gaining traction among patients and healthcare providers.

With ongoing technological advancements, increased insurance coverage for minimally invasive procedures, and a growing focus on women's reproductive health, the U.S. uterine fibroids treatment devices industry is poised for sustained growth.

U.S. Uterine Fibroids Treatment Devices Market Report Segmentation

• Based on technology, the surgical technologies segment dominates the market with the largest revenue share owing to the increasing prevalence of uterine fibroids among women, necessitating effective surgical interventions.
• Based on mode of treatment, the invasive treatment segment dominates the market with the largest revenue share owing to the high adoption of hysterectomy and myomectomy procedures, which offer definitive fibroid removal. Advancements in laparoscopic and robotic-assisted surgeries, along with strong insurance coverage, further solidified its market dominance.
• In January 2025, Hologic, Inc. acquired Gynesonics, Inc., a privately held company specializing in minimally invasive solutions for uterine fibroid treatment, for approximately USD 350 million. Gynesonics is renowned for its Sonata System, an innovative technology that combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation to treat symptomatic uterine fibroids without incisions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Third Party Perspective
  • 1.3.5. Primary research
  • 1.3.6. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Uterine Fibroids Treatment Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of uterine fibroids
    • 3.2.1.2. Advancements in minimally invasive procedures
    • 3.2.1.3. Increasing awareness and early diagnosis
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced treatment devices
• 3.3. U.S. Uterine Fibroids Treatment Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. U.S. Uterine Fibroids Treatment Devices Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Uterine Fibroids Treatment Devices Market Technology Movement Analysis
• 4.3. U.S. Uterine Fibroids Treatment Devices Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. Surgical Techniques
  • 4.4.1. Surgical Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Hysterectomy
    • 4.4.2.1. Hysterectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Myomectomy
    • 4.4.3.1. Myomectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Laparoscopic Techniques
  • 4.5.1. Laparoscopic Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Laparoscopic Myomectomy
    • 4.5.2.1. Laparoscopic Myomectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Myolysis
    • 4.5.3.1. Myolysis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Ablation Techniques
  • 4.6.1. Ablation Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Microwave Abalation
    • 4.6.2.1. Microwave Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Hydrothermal Abalation
    • 4.6.3.1. Hydrothermal Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Cyroablation
    • 4.6.4.1. Cyroablation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Ultrasound Abalation
    • 4.6.5.1. Ultrasound Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5.2. High Intensity Focused Ultrasound (HIFU)
      • 4.6.5.2.1. High Intensity Focused Ultrasound (HIFU) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5.3. MRI-guided Focused Ultrasound (MRgFUS)
      • 4.6.5.3.1. MRI-guided Focused Ultrasound (MRgFUS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Embolization Techniques
  • 4.7.1. Embolization Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Uterine Fibroids Treatment Devices Market: Mode of Treatment Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Uterine Fibroids Treatment Devices Market Mode of Treatment Movement Analysis
• 5.3. U.S. Uterine Fibroids Treatment Devices Market Size & Trend Analysis, by Mode of Treatment, 2018 to 2030 (USD Million)
• 5.4. Invasive Treatment
  • 5.4.1. Invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Minimally Invasive Treatment
  • 5.5.1. Minimally Invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Non-invasive Treatment
  • 5.6.1. Non-invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
• 6.2. Key Company Profiles
  • 6.2.1. Medtronic
    • 6.2.1.1. Company Overview
    • 6.2.1.2. Financial Performance
    • 6.2.1.3. Service Benchmarking
    • 6.2.1.4. Strategic Initiatives
• 6.3. Stryker
  • 6.3.1.1. Company Overview
  • 6.3.1.2. Financial Performance
  • 6.3.1.3. Service Benchmarking
  • 6.3.1.4. Strategic Initiatives
• 6.4. Boston Scientific Corporation
  • 6.4.1.1. Company Overview
  • 6.4.1.2. Financial Performance
  • 6.4.1.3. Service Benchmarking
  • 6.4.1.4. Strategic Initiatives
• 6.5. Insightec.
  • 6.5.1.1. Company Overview
  • 6.5.1.2. Financial Performance
  • 6.5.1.3. Service Benchmarking
  • 6.5.1.4. Strategic Initiatives
• 6.6. CooperSurgical Inc.
  • 6.6.1.1. Company Overview
  • 6.6.1.2. Financial Performance
  • 6.6.1.3. Service Benchmarking
  • 6.6.1.4. Strategic Initiatives
• 6.7. Hologic, Inc.
  • 6.7.1.1. Company Overview
  • 6.7.1.2. Financial Performance
  • 6.7.1.3. Service Benchmarking
  • 6.7.1.4. Strategic Initiatives
• 6.8. CONMED Corporation.
  • 6.8.1.1. Company Overview
  • 6.8.1.2. Financial Performance
  • 6.8.1.3. Service Benchmarking
  • 6.8.1.4. Strategic Initiatives
• 6.9. Merit Medical Systems.
  • 6.9.1.1. Company Overview
  • 6.9.1.2. Financial Performance
  • 6.9.1.3. Service Benchmarking
  • 6.9.1.4. Strategic Initiatives
• 6.10. Minerva Surgical, Inc.
  • 6.10.1.1. Company Overview
  • 6.10.1.2. Financial Performance
  • 6.10.1.3. Service Benchmarking
  • 6.10.1.4. Strategic Initiatives

관련자료